 |
Adam Bonislawski is the editor of GenomeWeb's ProteoMonitor. He covers proteomics and life science mass spectrometry. E-mail Adam Bonislawski and follow his GenomeWeb Twitter account at @ProteoMonitor. |
MRM-MS 'Core' to Caprion's Protein Dx Strategy in Wake of Acquisition by Chicago Growth Partners
July 27, 2012
MRM-MS 'Core' to Caprion's Protein Dx Strategy in Wake of Acquisition by Chicago Growth Partners
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Caprion Leading $21M Clinical Biomarker and Personalized Medicine Development Project
February 22, 2013 / ProteoMonitor - Agilent Partners with Integrated Diagnostics, Further Signaling Focus on MRM-MS as Clinical Platform
January 13, 2012 / ProteoMonitor - GenomeWeb Feature: The Unsteady March of Cancer Protein Biomarkers into the Clinic
May 10, 2013 / ProteoMonitor - 2012 Sees Rise of Targeted Proteomics and DIA-MS, Continued Clinical Push by Big Industry Players
January 4, 2013 / ProteoMonitor - Thallion Sells Stake in Caprion for $4.5M
July 19, 2012 / GenomeWeb Daily News